TH9619 / One-carbon Therapeutics - LARVOL DELTA

One-carbon Therapeutics AB…announced today the closing of an oversubscribed 153 million SEK ($16.2 million) private placement financing round supported by current and new investors and private Swedish family offices. (Drug Discovery News) - "One-carbon Therapeutics will use the net proceeds from the private placement to strengthen its financial position and expand its ongoing Phase 1/2 ODIN clinical study of TH9619, an MTHFD1/2 inhibitor, thereby further accelerating its momentum through a data-driven strategy."

Financing • Colorectal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Non Small Cell Lung Cancer • Squamous Cell Carcinoma of Head and Neck

ODIN: Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=43 | Recruiting | Sponsor: One-carbon Therapeutics AB

New P1/2 trial • Colorectal Cancer • Esophageal Cancer • Gastric Cancer • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

MTHFD1/2 inhibitor TH9619 in combination with PD-L1 blockade in NSCLC (CIMT 2025) - "Our data demonstrate that TH9619 can work in combination with the PD-L1 inhibitor Atezolizumab in the LL2 murine lung cancer model, and we investigate PD-L1 expression and CD8+ T cell infiltration by flow cytometry and immunofluorescence. This report investigates if TH9619 may enhance the therapeutic efficacy of immunotherapies targeting the PD-1/PD-L1 pathway."

Combination therapy • IO biomarker • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CD8 • MTHFD2